Cleveland·Miami·Basel·Tel AvivForce Multipliers  ·  Elevate Humanity
Home / Insights / Life Sciences and Healthcare
Insights

Life Sciences and Healthcare

Life sciences and healthcare is the LeverVenture mandate. These pieces cover biotech and gene therapy, diagnostics and precision medicine, medical devices and surgical robotics, digital and mental health, and longevity and neuroscience, written for the companies building them.

Field notes, diligence method, operating and capital Written by the partner or operator who did the work
§ 01  /  02
The archive

Filed under Life Sciences and Healthcare, newest first.

The most recent piece leads and every other piece in this category follows it, each with the line that says what it covers. The other categories are one link away.

Most recent
Life Sciences and Healthcare23 Oct 2026  ·  11 min read

Mapping a Digital Health Company's Real Provider Footprint

NPPES, state licensure lookups and CMS Care Compare, read together, test a digital health company's clinician and state claims before the data room opens.

Peleg ChevionBy Peleg Chevion
Read the piece
Browse by category
By author

Life Sciences and Healthcare

The full index

Everything else filed under Life Sciences and Healthcare, newest first.

Life Sciences and Healthcare16 Oct 2026  ·  10 min

Trial Site Density as an Early Commercial Signal

Recruiting Phase 3 cancer trials that gate eligibility on a biomarker list 92 sites on average against 39 for those that do not, an early read on testing demand.

Read this piece
Life Sciences and Healthcare02 Oct 2026  ·  9 min

The Investment Thesis You Can Be Held To

A thesis binds only through its exclusions. LeverVenture's investment thesis as one table: what we underwrite and what we do not, by sector and by structure.

Read this piece
Life Sciences and Healthcare22 Sep 2026  ·  9 min

How Medtech and Surgical Robotics Founders Should Approach Growth Capital

Medtech and surgical robotics founders face two questions before any capital conversation: the FDA pathway and the reimbursement pathway. This guide walks through both.

Read this piece
Life Sciences and Healthcare14 Sep 2026  ·  15 min

Funding the Longevity Economy: A Growth Capital Guide for Longevity and Neuro Founders

Longevity and neuro science is harder for generalist investors to underwrite. This guide walks founders through the validation, regulatory, and data questions growth-stage capital will ask.

Read this piece
Life Sciences and Healthcare04 Jul 2026  ·  7 min

When Your Operational Infrastructure Is the Fundraising Story: What Growth-Stage Founders Actually Get Scrutinized On

Growth-stage founders in life sciences, deep tech, and healthtech are increasingly scrutinized on operational infrastructure before investment history. Here's what that means for you.

Read this piece
Life Sciences and Healthcare16 Jun 2026  ·  5 min

AI Infrastructure for Life Sciences and Healthcare Founders: Where to Build, Where to Wait

A tactical breakdown of AI infrastructure decisions for founders in life sciences, digital health, and deep tech — what to own, what to rent, and what to deprioritize.

Read this piece
Life Sciences and Healthcare21 Apr 2026  ·  12 min

Quality of Earnings in a Company With No Earnings

A quality-of-earnings review of a pre-revenue biotech or diagnostics company replaces EBITDA with burn quality, grant accounting, milestone recognition and clinical accruals.

Read this piece
Life Sciences and Healthcare24 Feb 2026  ·  11 min

Mid-Market Healthcare: Why the Thesis Only Works Here

The healthcare middle market stated as six constraints, from revenue and ownership to leverage and state review, measured against the NCMM and PitchBook definitions.

Read this piece
Life Sciences and Healthcare10 Feb 2026  ·  10 min

Why Life Sciences, Why Now: The Thesis in Full

LeverVenture invests across five life sciences and healthcare sectors, each with one underwriting gate, and treats artificial intelligence as the accelerant inside all five.

Read this piece
Life Sciences and Healthcare14 Oct 2025  ·  9 min

Risk-Adjusted NPV, and Why Every Other Method Breaks on Clinical Risk

Risk-adjusted NPV weights each cash flow by the chance a drug program survives to it. Single-rate shortcuts break because clinical risk resolves in steps at phase gates.

Read this piece
Life Sciences and Healthcare30 Sep 2025  ·  8 min

The Diligence Checklist for a Life-Sciences Growth Round

The firm's working due diligence checklist for a life-sciences growth round, eight sections in order, with the clinical, regulatory and reimbursement items tied to their governing rules.

Read this piece
Life Sciences and Healthcare28 Aug 2025  ·  9 min

Precedent Transactions When There Are Four Comparables

Four 2024-25 biopharma takeovers, restated on one basis: the median premium is 102.5% cash only, 120.6% with CVRs risk-weighted, 214.4% if every milestone pays.

Read this piece
Life Sciences and Healthcare23 Jul 2025  ·  5 min

Precision Medicine Investment Landscape 2025

Precision medicine is five different businesses, not one market. Margin sits with regulatory linkage and proprietary data, not with sequencing throughput.

Read this piece
Life Sciences and Healthcare18 Jul 2025  ·  7 min

Precision Medicine Breakthroughs: Making Personalized Cancer Treatment Accessible

The binding constraint on precision oncology isn't the drugs — it's the biomarker test that has to happen first, and often doesn't in time.

Read this piece
Life Sciences and Healthcare15 Jun 2025  ·  7 min

Mental Health Tech: The $5.5B Market Opportunity

Demand was never the constraint in mental health tech. Who pays, through which channel, and whether they renew is what separates durable companies from churn.

Read this piece
Life Sciences and Healthcare10 Jun 2025  ·  5 min

Mental Health Technology: Breaking Down Treatment Access Barriers

An app is not a clinician. Mental health access is a workforce and licensure problem — task-shifting and interstate compacts expand capacity; booking software does not.

Read this piece
Life Sciences and Healthcare22 May 2025  ·  5 min

Gene Therapy Commercial Viability: From Approval to Patient Access

Approval is not the finish line for a gene therapy. Manufacturing, site-of-care access, payment architecture, and durability are separate commercial risks.

Read this piece
Life Sciences and Healthcare14 May 2025  ·  6 min

FDA Digital Health Guidance: Regulatory Clarity Accelerates Innovation

The FDA's predetermined change control plan lets an AI-enabled device keep learning after clearance without refiling for every update. That changes what's investable.

Read this piece
Life Sciences and Healthcare27 Mar 2025  ·  6 min

Digital Health: From Telemedicine to AI Diagnostics

Model accuracy is table stakes. AI diagnostic winners are decided by prospective validation, workflow integration, and who bears liability for a miss.

Read this piece
Life Sciences and Healthcare22 Mar 2025  ·  5 min

Democratizing Healthcare Access: Digital Platforms Bridging Rural Care Gaps

Rural healthcare access is a reimbursement and logistics problem, not a product problem. Broadband, hospital closures, and billing codes set the real ceiling.

Read this piece
Life Sciences and Healthcare08 Feb 2025  ·  5 min

Biotech Funding Environment: Post-IPO Window Analysis

When the biotech IPO window is shut, capital doesn't disappear — it changes shape. Which financing instrument a company reaches for is itself diligence.

Read this piece
§ 02  /  02
Research

The State of Growth Equity, 2026 edition.

The first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.

01

Executive summary

Free, no form. The findings, the method and every chart that carries one — complete, not a teaser, and the same text that opens the full report.

02

The full report

Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no list you did not ask to be on.

Go to the research
Contact

Have a question about something here, or want to discuss it? We would be glad to hear from you.

The 2026 study